Queen Elizabeth Hospital Birmingham

Running trials

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Takeda· Source

• Recruiting

  A Gaucher Disease Gene Therapy Trial With FLT201

  NCT07223944· Phase 3· Spur Therapeutics· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Rein Therapeutics· Source

• Recruiting

  Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

  NCT07053800· Phase 2· Autolus Limited· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

  NCT06243731· Takeda· Source

• Recruiting

  Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

  NCT07123155· Phase 2· Shionogi· Source

• Recruiting

  A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

  NCT07220564· Phase 1· Novo Nordisk A/S· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

  NCT06855771· Phase 2· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Calluna Pharma AS· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

• Recruiting

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

  NCT06747572· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

  NCT06628310· Phase 2· AbbVie· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Vicore Pharma AB· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  NCT06379789· Phase 1/2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia

  NCT06832371· Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Active, not recruiting

  A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

  NCT06360354· Phase 1· Amgen· Source

• Active, not recruiting

  Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

  NCT06353386· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Global Prospective Observational Registry of Patients With Pompe Disease

  NCT06121011· Amicus Therapeutics· Source

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Active, not recruiting

  Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

  NCT06046222· Phase 2· NS Pharma, Inc.· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Rescue of Nephrons With ALE.F02 (RENAL-F02)

  NCT06047171· Phase 2· Alentis Therapeutics AG· Source

• Recruiting

  GEKO Venous Thromboembolism Prevention Study

  NCT05476913· Firstkind Ltd· Source

• Active, not recruiting

  First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

  NCT06398743· Exact Sciences Corporation· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source

• Active, not recruiting

  A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

  NCT05630755· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

  NCT04939935· Phase 3· The University of Queensland· Source

• Recruiting

  A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  NCT05623020· Phase 3· Pfizer· Source

• Recruiting

  Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

  NCT05533697· Phase 1/2· ModernaTX, Inc.· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Pfizer· Source

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Shockwave Medical, Inc.· Source

Showing 50 of 59.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Haemophilia3 recruiting
• Lung cancer3 recruiting
• Childhood cancers2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Liver cirrhosis2 recruiting
• Melanoma2 recruiting
• Multiple myeloma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Pompe disease2 recruiting
• Type 1 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ANCA-associated vasculitis1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Cytomegalovirus infection1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Epilepsy1 recruiting
• Gaucher disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lupus (SLE)1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Polycystic kidney disease1 recruiting
• Prostate cancer1 recruiting
• Spinal cord injury1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

  NCT06940154· Phase 2· Connect Biopharm LLC· Source

• Terminated

  A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

  NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK

  NCT07602803· The Queen Elizabeth Hospital· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Terminated

  A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05161481· Phase 2· Boehringer Ingelheim· Source

• Terminated

  IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.

  NCT05975931· LivaNova· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Terminated

  Non-interventional Study Describing Healthcare Resource Utilisation and Clinical Outcomes Associated With VNS Therapy in UK.

  NCT04779814· LivaNova· Source

• Completed

  Trenza Embolization Device for Intrasaccular Aneurysm Treatment

  NCT04380350· Stryker Neurovascular· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Amicus Therapeutics· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

  NCT04166773· Phase 2· Eli Lilly and Company· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Gene Therapy Study in Severe Haemophilia A Patients (270-201)

  NCT02576795· Phase 1/2· BioMarin Pharmaceutical· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Primary biliary cholangitis6 works · 1 trial
• Cushing's syndrome5 works · 0 trials
• Fabry disease5 works · 0 trials